Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Sacituzumab Govitecan vs Treatment of Physician’s Choice in Metastatic or Locally Advanced Unresectable Urothelial Cancer
2020-002964-29Phase 3Active
- Sponsor
- Gilead Sciences
- Start
- Mar 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan in transitional cell carcinoma (TCC) and Renal pelvis urothelial carcinoma (UTUC) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Overall survival. Started Mar 2021; status: active.
02
Drugs
sacituzumab govitecan
03
Conditions
transitional cell carcinoma (TCC)Renal pelvis urothelial carcinoma (UTUC)
Beyond the preview
Go deeper on 2020-002964-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002964-29.